HDL-cholesterol modulation and its impact on the management of cardiovascular risk

Ann Clin Biochem 2008;45:122-128
doi:10.1258/acb.2007.007177
© 2008 Association for Clinical Biochemistry

 

This Article
Right arrow
Figures Only
Right arrow
Full Text
Right arrow

Full Text (PDF)

Right arrow
Alert me when this article is cited
Right arrow
Alert me if a correction is posted
Services
Right arrow
Email this article to a friend
Right arrow

Similar articles in this journal

Right arrow
Similar articles in PubMed
Right arrow
Alert me to new issues of the journal
Right arrow
Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow
Articles by Ferns, G.
Right arrow
Articles by Keti, V.
Right arrow Search for Related Content
PubMed
Right arrow
PubMed Citation
Social Bookmarking

What’s this?

Review Article


Gordon Ferns 1 2  and
Vuyolethu Keti 2


1 Postgraduate Medical School, University of Surrey, Daphne Jackson Road, Guildford, Surrey GU2 7WG, UK;
2 Royal Surrey County Hospital, Egerton Road, Guildford, Surrey GU2 7XX, UK


Corresponding author: Prof Gordon Ferns. Email: g.ferns{at}surrey.ac.uk

There is strong epidemiological evidence that HDL-cholesterol(HDL-C) is an independent cardiovascular risk factor. A lowHDL-C is a common finding in the general population, and isa feature of metabolic syndrome, the prevalence of which isincreasing globally. The importance of HDL-C as a coronary riskfactor is generally accepted, and has been incorporated intomost of the commonly applied risk engines. There are severalcauses of a low HDL-C, including rare genetic abnormalities,and more common conditions associated with lifestyle and drugtherapy. Not all of these are associated with an increased riskof coronary disease. A better understanding of HDL metabolismand the mechanisms by which it may exert its protective effectshas revealed why this may be the case. New therapeutic targetshave also been identified that may allow HDL-C to be raisedin patients with low levels. However, good clinical endpointstudies are still required to enable the setting of absolutetarget values for HDL-C in patients at high cardiovascular risk.


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What’s this?